The Pulmonary Fibrosis Foundation (PFF) recently announced the launch of the PFF Patient Registry, which will comprise the foundation’s first comprehensive collection of data from pulmonary fibrosis (PF) patients across America. The first patient was enrolled last week, kicking off patient enrollment in the registry,…
News
Antegrin Therapeutics recently announced that it is expanding its current medication portfolio to include anti-fibrosis agents that block proteins known as integrins. The drugs were originally discovered at the Center for World Health & Medicine (CWHM) at Saint Louis University. Antegrin already offers several medications that target conditions characterized by fibrosis, including pulmonary…
Researchers at Weill Cornell Medicine showed that starving a group of immune cells by inhibiting the activity of the enzyme Arginase-1 impairs the cells’ ability to induce an allergic response. The study, “Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation,” published in the journal…
Analysis of pooled data from three international, randomized, and placebo-controlled clinical trails — the Phase 2 TOMORROW trial and two Phase 3 INPULSIS trials — showed that nintedanib (Ofev) is an efficient and safe drug for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The study, “Nintedanib…
Researchers discovered that mice exposed to bleomycin — a common pulmonary fibrosis model — displayed more intense fibrotic activity if they lacked the signaling factor PTEN. The findings suggest that exploring the signaling pathway involving PTEN might offer new insights into disease mechanisms, and aid the search for new treatment…
Hyaluronan synthase 2 (HAS2) deletion from fibrotic fibroblasts induces senescence (gradual deterioration) in the cells and fibrotic clearance in mouse models of lung fibrosis. The findings, reported in the study “Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis” and published in the journal Matrix Biology, suggest…
Nintedanib (marketed as OFEV by Boehringer Ingelheim) has shown very good results in clinical trials in patients with idiopathic pulmonary fibrosis (IPF). Nevertheless, some patients still experience disease exacerbation when treated with the drug. A case study described the successful reinstallation of the drug after an exacerbation — raising hopes…
Men have higher rates of pulmonary fibrosis than women and tend to have a poorer survival. A study showed that mice exposed to silica, a known lung fibrosis trigger, have some sex-specific differences in their expression of the fibrotic factor SPP1, indicating that female sex hormones might alter molecular characteristics…
Synairgen, plc, recently reported positive data from its ongoing work, in partnership with Pharmaxis, to develop a lysyl oxidase type 2 enzyme (LOXL2) inhibitor as a new treatment for idiopathic pulmonary fibrosis (IPF). The results were derived from experiments in an in vitro model of IPF, using patients’ lung cells,…
C-type natriuretic peptide (CNP) is already known to protect against fibrosis in heart tissue. Researchers from the National Cerebral and Cardiovascular Center, Japan, have now shown that CNP can also improve lung fibrosis in a mouse model by preventing the formation of myofibroblasts. Given the importance of fibroblast cells in the…
